ANVS homework Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
set stop lose 12.50
entry $13
exit $16
Key stats
Market capitalization
180.423MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.45USD
About Annovis Bio, Inc
ISIN
US03615A1088
Sector
Health Technology
Industry
Pharmaceuticals: Major
Website
annovisbio.com
CEO
Maria-Luisa Maccecchini
Headquarters
Berwyn
Employees
3
Founded
2008
Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0